PWPaulina Wakula

Paulina Wakula

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paulina Wakula has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Alessio Alogna

    Department of Internal Medicine and Cardiology, Charité—Universitätsmedizin Berlin , Campus Virchow-Klinikum, Augustenburgerplatz 1, Berlin, 13353

    1 shared publication
  • Aleyde Van Eynde

    Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

    1 shared publication
  • Burkert Pieske

    Berlin Institute of Health (BIH) at Charité- Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Daniel Scherr

    Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria

    1 shared publication
  • David Zweiker

    Division of Cardiology, Medical University of Graz , Graz

    1 shared publication
  • Florian Blaschke

    Department of Internal Medicine and Cardiology, Charité—Universitätsmedizin Berlin , Campus Virchow-Klinikum, Augustenburgerplatz 1, Berlin, 13353

    1 shared publication

Latest Publications

  • Open Access

    Cellular Contribution to Left and Right Atrial Dysfunction in Chronic Arterial Hypertension in Pigs

    by Ge Jin, Martin Manninger, Gabriel Adelsmayr, Michael Schwarzl, Alessio Alogna, Patrick Schönleitner, David Zweiker, Florian Blaschke, Mohammad Sherif, Snjezana Radulovic, et al.

    Aims Atrial contractile dysfunction contributes to worse prognosis in hypertensive heart disease (HHD), but the role of cardiomyocyte dysfunction in atrial remodelling in HHD is not well understood. We investigated and compared cellular mechanisms of left (LA) and right atrial (RA) contractile dysfunction in pigs with HHD. Methods and results In vivo electrophysiological and magnetic resonance imaging studies were performed in control and pigs treated with 11‐deoxycorticosterone acetate (DOCA)/high‐salt/glucose diet (12 weeks) to induce HHD. HHD leads to significant atrial remodelling and loss of contractile function in LA and a similar trend in RA (magnetic resonance imaging). Atrial remodelling was associated with a higher inducibility of atrial fibrillation but unrelated to changes in atrial refractory period or fibrosis (histology). Reduced atrial function in DOCA pigs was related to reduced contraction amplitude of isolated LA (already at baseline) and RA myocytes (at higher frequencies) due to reduced intracellular Ca release (Fura 2‐AM, field stimulation). However, Ca regulation differed in LA and RA cardiomyocytes: LA cardiomyocytes showed reduced sarcoplasmic reticulum (SR) [Ca], whereas in RA, SR [Ca] was unchanged and SR Ca2+‐ATPase activity was increased. Sodium–calcium exchanger (NCX) activity was not significantly altered. We used ORM‐10103 (3 μM), a specific NCX inhibitor to improve Ca availability in LA and RA cardiomyocytes from DOCA pigs. Partial inhibition of NCX increased Ca2+ transient amplitude and SR Ca in LA, but not RA cells. Conclusions In this large animal model of HHD, atrial remodelling in sinus rhythm in vivo was related to differential LA and RA cardiomyocyte dysfunction and Ca signalling. Selective acute inhibition of NCX improved Ca release in diseased LA cardiomyocytes, suggesting a potential therapeutic approach to improve atrial inotropy in HHD.


  • Open Access

    The translation initiation factor eIF2β is an interactor of protein phosphatase-1

    by Paulina Wakula, Monique Beullens, Aleyde van Eynde, Hugo Ceulemans, Willy Stalmans, Mathieu Bollen

    It is reasonably well understood how the initiation of translation is controlled by reversible phosphorylation of the eukaryotic translation initiation factors eIF2α, eIF2Bϵ and eIF4E. Other initiation factors, including eIF2β, are also established phosphoproteins but the physiological impact of their phosphorylation is not known. Using a sequence homology search we found that the central region of eIF2β contains a putative PP1-(protein phosphatase-1) binding RVxF-motif. The predicted eIF2β-PP1 interaction was confirmed by PP1 binding and co-immunoprecipitation assays on cell lysates as well as with the purified components. Site-directed mutagenesis showed that eIF2β contains, in addition to an RVxF-motif, at least one other PP1-binding site in its C-terminal half. eIF2β functioned as an inhibitor for the dephosphorylation of glycogen phosphorylase and Ser51of eIF2α by PP1, but did not affect the dephosphorylation of Ser464 of eIF2Bϵ by this phosphatase. Strikingly, eIF2β emerged as an activator of its own dephosphorylation (Ser2, Ser67, Ser218) by associated PP1, since the substrate quality of eIF2β was decreased by the mere mutation of its RVxF-motif. These results make eIF2β an attractive candidate substrate for associated PP1 in vivo. The overexpression of wild-type eIF2β or eIF2β with a mutated RVxF-motif did not differentially affect the rate of translation, indicating that the binding of PP1 is not rate-limiting for translation under basal conditions.